To further evaluate the efficacy of the combined treatment with paclitaxel and the TCP inhibitor against VASH2-induced paclitaxel resistance in vivo, we established a BALB/c-nu xenograft model using H520VASH2 cells and analyzed the tumor control rate (Fig. 3I). This evidence concerns the gene VASH2 and neoplasm.